Home › Drug Codes › J Codes › J9286 · COLUMVI
Updated October 1st, 2026

COLUMVI J Code: J9286

Injection, glofitamab-gxbm, 2.5 mg

Login to unlock all benchmarks
Medicare Payment Limit ?
$2,859.117
/ HCPCS billing unit
APC Payment Limit ?
$2,859.117
/ HCPCS billing unit · APC 0720
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
2
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, glofitamab-gxbm, 2.5 mg
HCPCS Added Date January 1, 2024
Manufacturer Genentech
Route of Administration Intravenous
Generic Status Single-Source; Branded
Dosage Type Single-Dose
Dosage Form Concentrate | Solution, Concentrate

About COLUMVI

Columvi is a medication aligned to the HCPCS J Code: J9286 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the intravenous route and manufactured by Genentech.

According to CMS Drug Use Information: This medication is used to treat certain types of cancer (large B-cell lymphoma- LBCL, diffuse large B-cell lymphoma- DLBCL). Glofitamab works by slowing or stopping the growth of cancer cells.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
50242-0125-01 Columvi Genentech, Inc. 1 2.5 MG / 2.5 ML
50242-0127-01 Columvi Genentech, Inc. 4 10 MG / 10 ML
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

COLUMVI Pricing & Reimbursement

J9286 Private Payer Reimbursement
$2,931.11 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q4 2026

COLUMVI Claims Performance

Claims from Jan 2026 – Aug 2026
Claim Denial Rate 38.83%
Avg. Days to File 4.2days
Avg. Days to Pay 17.9days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9286 claims analytics on FocalPoint →
OnPoint Oncology

COLUMVI CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
JW / JZ modifiers apply

CMS has identified Columvi (J9286) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

COLUMVI Medically Unlikely Edits (MUE)

The most billing units of J9286 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 2.5 mg.

Practitioner Office & Hospital Outpatient
12 units / day
= 30 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

mg Enter a dose to see how many billing units it is and whether it is under the limit.

COLUMVI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma
Drug Class
Bispecific CD20-directed CD3 T Cell Engager [EPC]CD20-directed Antibody Interactions [MoA]CD3 Receptor Agonists [MoA]CD3-directed Antibody Interactions [MoA]Cytochrome P450 Inhibitors [MoA]Increased Cytokine Activity [PE]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there an available Columvi billing and coding guide?
Billing and coding information for COLUMVI can be found through GENENTECH, INC.. Visit Here →
Are there any available Columvi patient assistance programs?
COLUMVI patient assistance information can be found through GENENTECH, INC.. Visit Here →
Where can I find Columvi prescribing information?
COLUMVI prescribing information can be found at the link below: Visit Here →
Where can I find Columvi side effect information?
Information regarding COLUMVI's side effects can be found at MedlinePlus Visit Here →
Does billing COLUMVI require JZ/JW wastage modifiers?
CMS has identified COLUMVI(J9286) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.